Sun Pharmaceutical Industries: ILUMYA® (tildrakizumab-asmn) approved in the U.S. for the Treatment of Adults with Active Psoriatic Arthritis
Sun Pharmaceutical Industries (SUNPHARMA) filed a disclosure titled "ILUMYA® (tildrakizumab-asmn) approved in the U.S. for the Treatment of Adults with Active Psoriatic Arthritis". The company is valued at about ₹4.23 lakh crore.
What happened
Sun Pharmaceutical Industries (SUNPHARMA) filed a disclosure with the exchanges on 30 October 2026 at 08:05 AM titled "ILUMYA® (tildrakizumab-asmn) approved in the U.S. for the Treatment of Adults with Active Psoriatic Arthritis".
Company snapshot
Sun Pharmaceutical Industries is a large-cap company in the Healthcare sector, with a market value of about ₹4.23 lakh crore.
The stock last traded at ₹1,761, against a 52-week range of ₹1,583.7–₹2,046.9 (14.0% below the high).
Before this filing the shares had moved −5.6% over the month and −11.5% over three months. Average daily turnover over the last 20 sessions was about ₹243 crore.
Promoters held 54.48% at the end of Q1 FY27; 1.65% of promoter shares were pledged. Foreign institutions owned 14.53% and domestic institutions 22.18%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 13,851 | 2,278.6 | 9.5 |
| Q2 FY26 | 14,478 | 3,118 | 13 |
| Q3 FY26 | 15,521 | 3,368.8 | 14 |
| Q4 FY26 | 14,612 | 2,714 | 11.3 |
| Q1 FY27 | 15,300 | 2,894.8 | 12.1 |
What history shows
BCEIE's records show 1 previous approval filing from the company since May 2026.
Across 124 similar disclosures by other Healthcare companies, shares moved +0.4% on average the next day and +1.1% over five days; 52% of them rose the next day.
Market-wide, 1,541 approval filings with an impact score of 50 or more saw an average next-day move of +0.1%, with 47% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- 30 October 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.